A systematic review and meta-analysis of effectiveness and safety of therapy for overactive bladder using botulinum toxin A at different dosages

Hui-Yun Gu, Ju-Kun Song, Wen-Jun Zhang, Jin Xie, Qi-Sheng Yao, Wen-Jing Zeng, Chao Zhang _ and Yu-Ming Niu

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:90338-90350. https://doi.org/10.18632/oncotarget.20056

Metrics: PDF 1599 views  |   HTML 2629 views  |   ?  


Hui-Yun Gu1,*, Ju-Kun Song2,*, Wen-Jun Zhang3, Jin Xie4, Qi-Sheng Yao5, Wen-Jing Zeng6, Chao Zhang1 and Yu-Ming Niu1,5

1Center for Evidence-Based Medicine and Clinical Research, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China

2Department of Oral and Maxillary Surgery, Guizhou Provincial People's Hospital, Guiyang 550002, China

3Department of Ultrasound, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China

4Administrative Office, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China

5Department of Urinary Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China

6Department of Anesthesiology, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China

*Co first authors

Correspondence to:

Chao Zhang, email: [email protected]

Yu-Ming Niu, email: [email protected]

Keywords: overactive bladder, botulinum toxin A, urinary incontinence, incontinence quality of life, meta-analysis

Received: June 04, 2017     Accepted: July 25, 2017     Published: August 07, 2017


Purpose: To assess the effectiveness and safety of botulinum toxin A (BTX-A) at different dosages for overactive bladder (OAB).

Materials and Methods: The MEDLINE, EMBASE, and Cochrane Controlled Trials Register databases were searched through November 3, 2016 to identify relevant randomized controlled trials (RCTs).

Results: Eleven studies were identified in this meta-analysis. Compared with placebo, the urinary incontinence (UI) episodes per week as the primary outcomes, urodynamic parameters including maximum cystometric capacity (MCC), and maximum detrusor pressure (MDP) for neurogenic detrusor overactivity (NDO) at 6 weeks, and for idiopathic detrusor overactivity (IDO) at 36 weeks were evaluated. These and other outcomes for effectiveness of BTX-A at different dosages in two observation periods indicate that a dose greater than 50 U is significantly more effective for certain symptoms of OAB compared with placebo. However, there were no significant differences between some dosages. Compared with placebo, the outcomes of total adverse events for NDO and for IDO show that doses of 300 U and 200 U for NDO are associated with more complications.

Conclusions: In consideration that the treatments of BTX-A were with minimal, local, and manageable adverse effects, this meta-analysis demonstrates that BTX-A 200 U is recommended for management of NDO for short-term treatment for there was no significant difference from the larger dose of 300U. The short-term efficacies of BTX-A for IDO remain to be investigated.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20056